PLoS One 11 , e0149516, (2016)
EVX-101 is in development for adjunctive Serotonin Synthesis Amplification therapy in depression and obsessive-compulsive disorder (OCD) therapy when first-line serotonin reuptake inhibitor antidepressants alone are inadequate
With 18 evaluable pharmacokinetic profiles per group, it was possible to detect a twofold difference between two groups with 80% power
3 This is because most brain GLP-1 receptors are less accessible to the medication
These include a body mass index (BMI) of 35 kg/m or above (or 32.5 kg/m or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity, and previous unsuccessful attempts at weight loss through diet and exercise
Semaglutide and other weight loss injections, like Mounjaro, are similar